Abstract:Abstract Background Despite the evolution of therapeutic strategies for Crohn’s disease (CD), many patients exhibit resistance to numerous biological agents, necessitating a transition to other advanced therapies. Therefore, the early and accurate prediction of the response to biological agents in treating CD is crucial. We sought to evaluate potentially useful biomarkers in predicting clinical response to biological agents in the management of CD. Methods This retrospective cohort study included data from adult CD patients who were naïve to biological treatments and maintained regular follow-up at a tertiary referral hospital between January, 2017 to June, 2022. Two prediction models were built to predict the Crohn's Disease Activity Index (CDAI) response at 12 weeks in its ordinal scale. The two clinical models included age, gender, and previous CD surgery. In model-1, we included 8-weeks neutrophile-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in their log scale as biomarkers of interest. Model-2 had 8-weeks neutrophile, platelet, monocyte, and lymphocyte counts in their natural scale. We built the prediction models using proportional odds model. Performance metrics were C-statistic for discrimination, brier score, visual calibration curve with bootstrap internal validation were used. Results A total of 104 patients were included, with a male predominance of 57.7% of the sample. The median age of the participants was 26 years (IQR: 21.00 – 36.00), and the median CDAI score was 237 (IQR: 125.25 – 256.0). Additionally, 43.3% of our population had undergone previous IBD surgery . The majority of the cohort initiated their treatment infliximab (59.6%), followed by adalimumab (35.6%). Model-1 has C-statistic of 0.678 compared to 0.682 for model-2. Brier scores for models 1 and 2 were 0.187 and 0.180, respectively. However, visual calibration curves showed better calibration of model-1 after bootstrapping internal validation corrected for over optimism. Odds ratio (OR) estimates of having higher odds of severe CDAI score at 12 weeks for model 1 were being female (OR: 2.20, 95% CI 1.04 –4.66; p = 0.04), higher NLR at week 8 (OR: 1.94, 95% CI 1.03– 3.65; p = 0.04), higher PLR at week 8 (OR 1.38, 95% CI 1.05– 1.8; p = 0.02), and higher CDAI score prior to the initiation of biological therapy (OR: 2.15, 95% CI 1.12– 4.13; p = 0.02). Conclusion The clinical prediction model that includes potentially useful biomarkers such as NLR and PLR at 8-weeks were well calibrated to predict a CDAI score at week 12 for the treatment response. Clinicians may find useful to implement prediction models in their clinical practice to evaluate the response of their patients.

P699 Machine Learning-based Prediction for Early Progression in Korean Crohn’s disease: Results from the IMPACT Study

Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends

P249 Development and validation of a novel model to predict disease behavior progression in Crohn's disease patients with intestinal stenosis

Linking gene expression to clinical outcomes in pediatric Crohn's disease using machine learning

Prediction of Crohn’s Disease Stricturing Phenotype Using a NOD2-derived Genomic Biomarker

Single-Cell Sequencing-Based Validation of T Cell-Associated Diagnostic Model Genes and Drug Response in Crohn's Disease

Machine learning gene expression predicting model for ustekinumab response in patients with Crohn's disease

A Machine Learning-Based Diagnostic Model for Crohn’s Disease and Ulcerative Colitis Utilizing Fecal Microbiome Analysis

TNFSF15 Variant Predicts Disease Progression in Chinese Patients with Crohn’s Disease

Development and Validation of Predictive Models for Crohn's Disease Patients with Prothrombotic State: a 6-Year Clinical Analysis.

Comparison and development of machine learning for thalidomide-induced peripheral neuropathy prediction of refractory Crohn's disease in Chinese population

P1020 Developing and Validating a Clinical Prediction Model Using Biomarkers to Assess Clinical Response and Severity of Crohn's Disease 12 Weeks After Initiation of Biological Therapy

Crohn's Disease Candidate Gene Alleles Predict Time to Progression from Inflammatory B1 to Stricturing B2, or Penetrating B3 Phenotype.

Identification of key biomarkers for predicting CAD progression in inflammatory bowel disease via machine‐learning and bioinformatics strategies

Genetic risk factors predict disease progression in Crohn’s disease patients of the Swiss inflammatory bowel disease cohort

Integrated multiple microarray studies by robust rank aggregation to identify immune-associated biomarkers in Crohn's disease based on three machine learning methods

P624 Development and Validation of a Clinical Decision Support Tool to Predict Outcomes of ustekinumab Treatment in Patients with Crohn’s Disease

A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor Α Therapy in Crohn’s Disease

Machine learning to predict early TNF inhibitor users in patients with ankylosing spondylitis

Mobile monitoring system detects the disease activity pattern and shows the association with clinical outcomes in patients with newly diagnosed Crohn's disease

Development of a Predictive Model to Distinguish Crohn's Disease from Other Etiologies